The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13

Chronic Kidney Diseases Clinical Trial

Official title:

The Effect of Previous Pneumococcal Immunization on the Immune Response of Adult Patients With Severe Chronic Kidney Disease to Prevnar 13

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02370069
• Other study ID #: RP-232-08262014
• Status: Completed
• Phase: Phase 4
• Start date: June 2015
• Est. completion date: August 2020

Study information

• Verified date: September 2021
• Source: Lakehead University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with severe chronic kidney disease (CKD) are at a great risk for infection due to their immune system being suppressed. Pneumococcal infection is particularly common and often results in death due to inflammation of lung (pneumonia) or the whole body (sepsis). This infection can be prevented using vaccines which help build protective immunity. The currently recommended pneumococcal vaccine (Pneumovax), however, is often inefficient in this group of patients. There is thus an urgent need to improve the existing vaccination policy.

The goal of this research is to optimize pneumococcal vaccination of patients with severe CKD. Many patients suffering from CKD have already been vaccinated with Pneumovax. Because this vaccine has low immunogenicity in immunocompromised individuals, they may still develop infection. A new vaccine, Prevnar13, has superior immunogenicity and has been recently approved for immunization. There is, however, no specific policy regarding immunization of adult CKD patients, and it is furthermore unknown whether previous Pneumovax immunization negatively affects immune response to Prevnar13.

In order to test whether previous immunization with Pneumovax affects the immune response of severe CKD patients to Prevnar 13, the investigators will immunize two groups of adult stage 4 and 5 CKD patients with one dose of Prevnar 13 and will assess their initial immunological response, its longevity, and vaccine safety. The first group will consist of patients who had been previously immunized with Pneumovax, and the second group will include participants with no history of pneumococcal vaccination.

Antibody levels and opsonophagocytic activity (OPA) will be quantified. The longevity of the immune response will be assessed. As a secondary objective, the immune response will be analyzed in the context of demographic and clinical characteristics of the vaccinated participants.

Description:

Adult patients with severe chronic kidney disease (CKD) are immunocompromised and known to have an increased risk of pneumococcal infection. To prevent the infection, immunization with pneumococcal polysaccharide vaccine (PPV23) is currently recommended in Canada; however, the vaccine effect in these patients is suboptimal because of their immune dysfunction. The second-generation pneumococcal vaccines (polysaccharide-protein conjugate) have superior immunogenicity in some immunocompromised adult individuals. In Canada, Prevnar 13 has recently been recommended by the NACI for certain categories of immunocompromised adults, such as HSCT recipients and HIV-positive patients. However, the NACI has concluded that there is currently insufficient evidence to recommend the use of Prevnar 13 in patients with chronic kidney disease. No published data on the use of pneumococcal conjugate vaccines in adults with CKD are available. Moreover, it is unknown whether a previous immunization with PPV23 may have a negative effect on the immune response to Prevnar 13 in these patients. Such a possibility exists due to the memory B-cells' depletion following immunization with pure polysaccharide antigens. In this case, additional doses of Prevnar 13 may be required to achieve the optimal protection. The conjugate vaccine will then expand the B-cell pool available to respond to subsequent antigen challenge. To test whether previous immunization with PPV23 affects the immune response of severe CKD patients to Prevnar 13, we will immunize two groups of adult stage 4 and 5 CKD patients attending the Thunder Bay Regional Health Sciences Centre with one dose of Prevnar 13 and will assess their initial immunological response, its longevity, and vaccine safety. The first group will consist of patients who had been immunized with PPV23 more than one year prior to the enrollment in this study and the second group will include patients without history of pneumococcal vaccination. Fold increase in antibody levels and OPA, as well as longevity of the immune response over a one-year period will be assessed as the surrogate for protection against pneumococcal infection. The immune response will be analyzed in the context of demographic and clinical characteristics of the vaccinated patients. All infectious episodes in the study participants will be recorded throughout one year of observation. We will also record all vaccine adverse effects following immunization and compare their frequency and severity between the two groups. The anticipated results of this trial will provide essential evidence to justify the use of Prevnar 13 for immunization of adult CKD patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 138
• Est. completion date: August 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females of 18 years of age or older at the time of the vaccination

• Severe chronic kidney disease (Stage 4 and 5)

Exclusion Criteria:

• immunization with PPV23 within the last year

• any confirmed or suspected immunodeficiency condition, including human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency

• history of allergic disease or reactions likely to be exacerbated by any component of the vaccine

• history of allergic disease likely to be stimulated by the vaccination

• history or records of immunosuppressive therapy (with the exception of topical corticosteroids) for more than 14 days and within 6 months of vaccination

• history or evidence of administration of immunoglobulins and/or any blood products during the study period or within the three months preceding the study vaccine

• use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the study vaccine

• administration of a vaccine during the period starting one month before the dose of vaccine and ending one month after

• pregnancy

Related Conditions & MeSH terms

• Chronic Kidney Diseases
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Biological:
• Prevnar 13
One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.

Locations

Country	Name	City	State
Canada	Thunder Bay Regional Health Sciences Centre	Thunder Bay	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Lakehead University

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Ulanova M, Huska B, Desbiens A, Gaultier GN, Domonkos V, McCready WG. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease. Vaccine. 2021 Jan 22;39(4):699-710. doi: 10.1016/j.vaccine.2020.12.035. Epub 2020 Dec 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	immunogenicity (Fold increase in serotype-specific antibody levels 28 days post-immunization as compared to baseline)	Fold increase in serotype-specific antibody levels 28 days post-immunization as compared to baseline	0 days, 28 days
Primary	immunogenicity (Increase in OPA titres 28 days post-immunization)	Increase in OPA titres 28 days post-immunization	28 days
Secondary	Longevity of the immune response (Persistence of antibody one year post-immunization)	Persistence of antibody one year post-immunization	365 days
Secondary	Longevity of the immune response (Persistence of OPA titres one year post-immunization)	Persistence of OPA titres one year post-immunization	365 days
Secondary	Clinical effect (Number of all infectious episodes during one year post-immunization)	Number of all infectious episodes during one year post-immunization	365 days